Sunesis presents Vecabrutinib trial data at the EHA annual meeting

	The Phase 1b/2 clinical trial assessed the efficacies of vecabrutinib in patients suffering from CLL & other B-Cell related malignancies.
	The preliminary data reported at the EHA meeting was from over 23 patients that were treated in the clinical trial.


Sunesis Pharmaceuticals Inc. (Sunesis), a renowned California based pharmaceutical firm, has reportedly presented the results from a Phase 1b/2 clinical trial that assessed the efficacies of vecabrutinib.

Reports cite, vecabrutinib is the company’s non-covalent BTK inhibitor that is focused towards treating adults suffering from refractory/relapsed Chronic Lymphocytic Leukemia (CLL) as well as other B-Cell related malignancies.

According to a press release by Sunesis, the results of the clinical trial were presented on June 15, 2019 during a poster session named ‘Chronic Lymphocytic Leukemia & related disorders – Clinical’ at the             European Hematology Association (EHA) annual meeting held in Amsterdam.

The Interim CEO of Sunesis, Dayton Misfeldt stated that the company is encouraged by the results presented at the meeting as it demonstrates vecabrutinib’s safety profile, that it is well-tolerated, and also gives evidence of effective clinical activity in both CLL & other B-cell related malignances. Misfeldt further added that the drug candidate’s median steady-state continues to increase through concentration with dose, approaching levels that are expected to facilitate a greater clinical activity and consistent BTK inhibition.

For the record, the company is currently dosing its trial patients in a 200mg cohort. Momentum of the clinical trial continues to pick-up as it is witnessing a strong pace of enrollment.

The preliminary data presented at the EHA was made available from over 23 patients that were treated under the clinical trial, including two patients suffering from Waldenstrom Macroglobulinemia (WM), two patients suffering from Mantle Cell Lymphoma (MCL) and 19 patients suffering from CLL.

It is reportedly expected that the company would unveil more data from additional cohorts as it completes the Phase 1b study and moves on to Phase 2 later in the year.

Source Credit:

http://ir.sunesis.com/news-releases/news-release-details/sunesis-pharmaceuticals-announces-presentation-preliminary-0

https://www.globenewswire.com/news-release/2019/06/15/1869291/0/en/Sunesis-Pharmaceuticals-Announces-Presentation-of-Preliminary-Data-from-Phase-1b-2-Trial-of-Vecabrutinib-in-Patients-with-CLL-and-Other-B-Cell-Malignancies-at-EHA-Annual-Meeting.html